Ciprofloxacin/hydrocortisone otic Pregnancy and Breast Feeding Warnings
Ciprofloxacin/hydrocortisone otic is also known as: Cipro HC
Overview
If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Ciprofloxacin/Hydrocortisone while you are pregnant. It is not known if Ciprofloxacin/Hydrocortisone is found in breast milk after topical use. Do not breast-feed while taking Ciprofloxacin/Hydrocortisone .
Ciprofloxacin/hydrocortisone otic Pregnancy Warnings
Ciprofloxacin-hydrocortisone otic has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal embryotoxicity or teratogenicity, although maternal toxicity in some animal studies resulted in increased incidence of abortion. There are no controlled data in human pregnancy. Systemic ciprofloxacin has been shown to distribute into amniotic fluid. Concentrations reported were 57% (at 2 to 4 hours post dose) to 1000% (at 10 to 12 hours post dose) of that found in maternal serum. Cartilage damage and arthropathies associated with ciprofloxacin have been reported in immature animals of various species, giving rise to concern over its possible toxic effects on human fetal bone formation. Animal studies have shown corticosteroids to be teratogenic in mice and rabbits following multiple dose topical application. However, limited data indicate that systemic absorption after otic administration of ciprofloxacin-hydrocortisone is extremely low. Ciprofloxacin-hydrocortisone otic should only be given during pregnancy when benefit outweighs risk.
Ciprofloxacin/hydrocortisone otic Lactation Warnings
There are no data on the excretion of ciprofloxacin-hydrocortisone otic into human milk. Concentrations of orally administered ciprofloxacin found in breast milk have ranged from 85% (at 24 hours post dose) to 214% (at 4 hours post dose) of maternal serum concentration. In one case report, an infant developed perforated pseudomembranous colitis following ingestion of ciprofloxacin via the mother's milk. In addition, quinolone-induced cartilage erosion and arthropathies that have been observed in juvenile animals render some concern over its possible toxic effects on the developing joints of nursing infants. However, limited data indicate that systemic absorption after otic administration is extremely low. Plasma levels of ciprofloxacin and hydrocortisone are expected to be below the level of quantitation after administration of 3 drops of suspension into the ear. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue the drug or to discontinue nursing, taking into account the importance of the drug to the mother.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
